{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-073502","form_type":"8-K","ticker":"HRTX","cik":"0000818033","company_name":"HERON THERAPEUTICS, INC. /DE/","filed_at":"2026-02-26T23:59:59+00:00","discovered_at":"2026-05-14T18:02:37.769262+00:00","generated_at":"2026-05-15T23:58:01.878070+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Heron Therapeutics reports 2025 net revenue $154.9M, up 7.4%; issues 2026 guidance $173-183M","bullets":["Full-year 2025 net revenue $154.9M (+7.4% YoY); Q4 net revenue $40.6M (-0.5% vs Q4 2024).","Acute care franchise grew 65.1% to $49.6M; ZYNRELEF +49%, APONVIE +156%.","Oncology franchise declined 7.8% to $105.3M; CINVANTI -3.3%, SUSTOL -39.9%.","2026 guidance: net revenue $173-183M, adjusted EBITDA $10-20M.","Cash $46.6M; ZYNRELEF J-code effective Oct 2025; prefilled syringe FDA target mid-to-late 2027."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-073502","json":"https://secwatch.observer/filing/0001193125-26-073502.json","markdown":"https://secwatch.observer/filing/0001193125-26-073502.md","text":"https://secwatch.observer/filing/0001193125-26-073502.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/818033/000119312526073502/0001193125-26-073502-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/818033/000119312526073502/hrtx-20260226.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T23:58:01.878070+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}